Overview
Description
Huadong Medicine Co., Ltd. engages in the production and sale of antibiotics, proprietary Chinese medicine, chemical synthetic medicine, and genetic engineering drugs. It involves in wholesale, retail, and distribution of Chinese and western medicine, Chinese herbal medicine, medical apparatus and instruments. Its products include Chinese medicine, drug immune agents, endocrine drugs, gastrointestinal agents, active pharmaceutical ingredient, hepatitis B medicine, and antineoplastic agents. The company was founded on March 31, 1993 and is headquartered in Hangzhou, China.
Healthcare Healthcare Services Healthcare Support Services China
Financials
Key metrics
| Market capitalisation, EUR | 8,512 m |
| EPS, EUR | 0.27 |
| P/B ratio | 2.9 |
| P/E ratio | 18.7 |
| Dividend yield | 2.35% |
Income statement (2024)
| Revenue, EUR | 5,352 m |
| Net income, EUR | 451 m |
| Profit margin | 8.43% |
What ETF is Huadong Medicine Co., Ltd. in?
There are 26 ETFs which contain Huadong Medicine Co., Ltd.. All of these ETFs are listed in the table below. The ETF with the largest weighting of Huadong Medicine Co., Ltd. is the JPMorgan China A Research Enhanced Index Equity (ESG) UCITS ETF USD (dist).
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
